N/A
N=63
Consortium to Disseminate and Understand Implementation of Opioid Use Disorder Treatment
Opioid Medication Assisted Treatment
Bottom Line
View on ClinicalTrials.gov: NCT04178551 ↗Enrolled (actual)
63
Serious AEs
—
Results posted
Nov 2025
Primary outcome: Primary: Number of Patients Within Participating Sites With OUD Initiating MOUD During the Implementation Facilitation Period in Implementation Sites. This Will be Compared to Pre-implementation. — 2116; 974 patients within participating sites
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Implementation Facilitation (Other)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Sep 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients Within Participating Sites With OUD Initiating MOUD During the Implementation Facilitation Period in Implementation Sites. This Will be Compared to Pre-implementation. |
2116; 974 | — |
| PRIMARY Number of Patients Within Participating Sites With OUD Retained on MOUD at 90 Days During the Implementation Period (i.e. Treatment Retention). This Will be Compared to Pre-implementation. |
1017; 357 | — |
| PRIMARY Number of Providers Prescribing MOUD During Implementation |
474; 258 | — |
| PRIMARY Number of Unique Implementation Strategies Used as Measured by the Expert Recommendations for Implementing Change (ERIC) Survey |
6 | — |
| PRIMARY Number of Providers With X-waiver During the Implementation Period |
1554; 1128 | — |
| PRIMARY Count of Implementation Strategies as Measured by the Expert Recommendations for Implementing Change (ERIC) Survey |
10 | — |
| SECONDARY Percentage of Patients With OUD Who Experienced a Fatal Opioid-related or Other Drug Overdose During Implementation |
5; 6 | — |
| SECONDARY Percentage of Patients With OUD Who Experienced Opioid-related or Other Drug Overdose During Implementation |
272; 188 | — |
| SECONDARY Use of Sedative Prescriptions During Implementation Among Patients With OUD |
1538; 888 | — |
Summary
Opioid use disorder (OUD) is a major cause of illness and death among Veterans for which effective treatment is a major priority of the Veterans Health Administration (VHA). Expanding access to alternatives to opioid medications for chronic pain management is also a leading priority. Effective medications for OUD (MOUD) are available, but their availability and use among Veterans varies across VHA. The aims of this study are to pull together the efforts of six individual pilot projects into a single project. The purpose of combining the projects is to maximize the value of the individual projects to VHA and to provide information to guide strategies to increase access and use of MOUD and alternative therapies for pain in VHA nationally. The researchers leading the individual projects will make use of their partnerships with Veterans Integrated Service Network (VISN) leaders in order to develop a combined effort toward increased dissemination and use of MOUD that spans 9 VISNs and 63 sites.
Eligibility Criteria
Inclusion Criteria
-All Veterans on prescribed opioid treatment and/or with opioid use disorder who are enrolled at participating implementation sites.
Exclusion Criteria
-None
Data sourced from ClinicalTrials.gov (NCT04178551). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.